Difference between revisions of "Encorafenib (Braftovi)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
||
| Line 16: | Line 16: | ||
[[Category:Mutation-specific medications]] | [[Category:Mutation-specific medications]] | ||
| − | + | ||
[[Category:BRAF inhibitors]] | [[Category:BRAF inhibitors]] | ||
Revision as of 23:10, 28 February 2020
General information
Class/mechanism (from NCI Drug Dictionary): An orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway.
Diseases for which it is used
History of changes in FDA indication
- 6/27/2018: Initial FDA approval in combination with Binimetinib (Mektovi) for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Also known as
- Code name: LGX818
- Brand name: Braftovi